Identifying safety concerns from genetic data: Lessons from the development of CCR5 inhibitors

Antiviral Therapy

Volumn 12, Issue 2, 2007, Pages 147-148

  Telenti, Amalio ^a   Egger, Matthias ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST;

CELL FUNCTION; CELL SURVIVAL; CLINICAL TRIAL; EDITORIAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KILLER CELL; META ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

ARTHRITIS, RHEUMATOID; CYCLOHEXANES; DRUG DESIGN; GENOTYPE; HEPATITIS C; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; META-ANALYSIS; MULTIPLE SCLEROSIS; MUTATION; PHARMACOGENETICS; RECEPTORS, CCR5; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TRIAZOLES;

EID: 34147112358     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (22)

1. Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 2004; 5:645-656.
2. Sabeti PC, Walsh E, Schaffner SF, et al. The case for selection at CCR5-Δ32. PLoS Biol 2005; 3:e378.
3. Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006; 296:815-826.
4. Khan IA, Thomas SY, Moretto MM, et al. CCR5 is essential for NK cell trafficking and host survival following Toxoplasma gondii infection. PLoS Pathog 2006; 2:e49.
5. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 2005; 202:1087-1098.
6. Rahbar R, Murooka TT, Hinek AA, et al. Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replication. J Virol 2006; 80:7245-7259.
7. Floto RA, MacAry PA, Boname JM, et al. Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Science 2006; 314:454-458.
8. Ank N, Petersen K, Malmgaard L, Mogensen SC, Paludan SR. Age-dependent role for CCR5 in antiviral host defense against herpes simplex virus type 2. J Virol 2005; 79:9831-9841.
9. Machado FS, Koyama NS, Carregaro V, et al. CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi. J Infect Dis 2005; 191:627-636.
10. Belnoue E, Kayibanda M, Deschemin JC, et al. CCR5 deficiency decreases susceptibility to experimental cerebral malaria. Blood 2003; 101:4253-4259.
11. Abel L, Casanova JL. Human genetics of infectious diseases: fundamental insights from clinical studies. Semin Immunol 2006; 18:327-329.
12. Picard C, Casanova JL, Abel L. Mendelian traits that confer predisposition or resistance to specific infections in humans. Curr Opin Immunol 2006; 18:383-390.
13. Casrouge A, Zhang SY, Eidenschenk C, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006; 314:308-312.
14. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148-155.
15. Prahalad S. Negative association between the chemokine receptor CCR5-A32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun 2006; 7:264-268.
16. Crabb C. GlaxoSmithKline ends aplaviroc trials. AIDS 2006; 20:641.
17. Schlesselman JJ. Case-Control Studies: Design, Conduct, Analysis. 1982; pp. 69-81. Oxford: Oxford University Press.
18. Gonzalez E, Dhanda R, Bamshad M, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1-α: impact on the epidemiology of the HIV-1 pandemic. PNAS 2001; 98:5199-5204.
19. Deng HW. Population admixture may appear to mask, change or reverse genetic effects of genes underlying complex traits. Genetics 2001; 159: 1319-1323.
20. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006; 203:35-40.
21. Thio CL, Astemborski J, Bashirova A, et al. Genetic protection against HBV conferred by CCR5 Δ32: evidence that CCR5 contributes to viral persistence. J Virol 2006; 81:441-445.
22. nd edn 2001; pp. 211-227. London: BMJ Books.